Skip to main content

Diana Gomez Manjarres, MD : Research

Critical Care Specialist

Photo of Diana Gomez Manjarres
(352) 273-8740 MyUFHealth

Active clinical trials

1493-0002

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis…

Investigator
Diana Gomez Manjarres
Status
Accepting Candidates
Ages
40 Years - N/A
Sexes
All
IPF/ILD PRO Registry

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other…

Investigator
Diana Gomez Manjarres
Status
Accepting Candidates
Ages
21 Years - N/A
Sexes
All

My publications

Filter publications

8 publications

2025

The evolving role of MRI in pulmonary sarcoidosis: Comparative analysis with PFTs and progression markers.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG

PubMed • Publisher's site

2025

Pathological features of connective tissue disease-associated interstitial lung disease in transbronchial cryobiopsies.

Histopathology

PubMed • Publisher's site

2023

Pathologic Criteria for the Diagnosis of Usual Interstitial Pneumonia vs Fibrotic Hypersensitivity Pneumonitis in Transbronchial Cryobiopsies.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

PubMed • Publisher's site

2023

Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial.

JCI insight

PubMed • Publisher's site

2022

Hypersensitivity Pneumonitis With and Without Autoimmune Features: A Clinical Comparative Analysis.

Lung

PubMed • Publisher's site